Polyclonal Antibodies Market Report 2026

Polyclonal Antibodies Market Overview

• Polyclonal Antibodies market size has reached to $1.48 billion in 2025 • Expected to grow to $2.1 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: The Increasing Prevalence Of Cancer Driving The Growth Of The Polyclonal Antibodies Market Due To Expanding Research And Treatment Applications • Market Trend: Polyclonal Antibodies Offer Promising Therapeutic Options for High-Risk COVID-19 Patients • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Polyclonal Antibodies Market?

Polyclonal antibodies are a type of antibody that is derived from multiple clones of B-cells, each producing a unique antibody molecule. Life science and translational medicine researchers frequently employ them because of their ease of handling for immunization and bleeding purposes. The main products of polyclonal antibodies are primary antibodies and secondary antibodies. A primary antibody refers to one of the antibodies present in the polyclonal mixture that specifically binds to the target antigen. Primary antibodies play a crucial role in various applications, including immunohistochemistry, Western blotting, ELISA, and other immunological assays. The sources of polyclonal antibodies are rabbits, goats, sheep, and others that are used for research, diagnostics, and therapy by academic and research centers, pharmaceutical and biotechnology companies, diagnostic centers, and hospitals.

What Is The Polyclonal Antibodies Market Growth Forecast?

The polyclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $2.1 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to expansion of precision medicine initiatives, growth in therapeutic antibody applications, technological advancements in antibody production, rising investments in diagnostics research, increasing collaborations between pharma and research institutes. Major trends in the forecast period include advanced polyclonal antibody production techniques, custom antibody development services, increasing use in diagnostic applications, growth in therapeutic research applications, expansion of academic and pharmaceutical research collaborations.

What Is The Driver Of The Polyclonal Antibodies Market?

The increasing prevalence of cancer is expected to propel the growth of the polyclonal antibodies market going forward. Cancer is a group of diseases characterized by uncontrolled cell growth and proliferation, leading to tissue damage and potential metastasis, and it remains a major cause of morbidity and mortality worldwide. The rise in cancer cases is driven by factors such as aging populations, lifestyle changes, and environmental exposures. Polyclonal antibodies are widely used in cancer research and treatment for biomarker detection, immunohistochemistry, targeted therapy, and immunotherapy, improving diagnosis, treatment, and patient outcomes. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases are projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the polyclonal antibodies industry.

Key Players In The Global Polyclonal Antibodies Market

Major companies operating in the polyclonal antibodies market are Abcam plc, GenScript Biotech Corporation, Merck KGaA, Thermo Fisher Scientific Inc., Becton Dickinson and Company, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Creative Diagnostics, Agilent Technologies, Analytik Jena GmbH, Atlas Antibodies, Danaher Corporation, DC Biosciences Ltd., ImmonoPresice Antibodies Ltd, Fujirebio, Omega BioTek Inc., Abnova Corporation, Santa Cruz Biotechnology Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., IGY Life Sciences, Genway Biotech, Good Biotech, Gallus Immunotech Inc., BioGenes GmbH, Capralogics Inc., Bio X Cell

Global Polyclonal Antibodies Market Trends and Insights

Major companies operating in the polyclonal antibodies market are focusing on developing advanced solutions, such as hyperimmune antibody therapies, to enhance patient outcomes, reduce severe complications, and improve immune responses. Hyperimmune antibody therapies involve the use of polyclonal antibodies derived from plasma donors with high levels of neutralizing antibodies, providing targeted immune protection against viral infections. For instance, in April 2023, SAB Biotherapeutics, a US-based biotechnology company, announced positive Phase 3 trial results for SAB-185, its fully human polyclonal antibody therapy, in patients at high risk for severe COVID-19 complications. Designed to neutralize SARS-CoV-2 effectively, SAB-185 demonstrated safety and efficacy, highlighting the potential of polyclonal antibody therapies to improve treatment outcomes in vulnerable patient populations.

What Are Latest Mergers And Acquisitions In The Polyclonal Antibodies Market?

In September 2024, Leinco Technologies, a US-based biotech company, acquired QED Biosciences for an undisclosed amount. Through this acquisition, Leinco aims to enhance and expand its collection of antibodies (both monoclonal and polyclonal), along with its related products and services for research and diagnostic uses. QED Biosciences is a US-based company that offers polyclonal rabbit antibody production.

What Defines the Polyclonal Antibodies Market?

The polyclonal antibodies market consists of sales of anti-cd4 polyclonal antibodies, anti-her2 polyclonal antibodies, and anti-insulin polyclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Polyclonal Antibodies Market Report 2026?

The polyclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the polyclonal antibodies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.